<b>Gapping up <br/>In reaction to strong earnings/guidance: </b>GMCR +19.1%, GFI +15.7%, CTRP +12%, WB +8.4%, CRM +4.9%, CRH +4.6%, PERY +4%, NTAP +2.1%, SINA +1.9%, CVO +0.6%, SJM +0.5%<br/><br/><b>M&A news: </b>CLDN +64.9% (Celladon and Eiger BioPharmaceuticals sign merger agreement; concurrent financing of $39.5 million from investor syndicate), BZC +3.5% (TransDigm Group Incorporated (TDG) and Breeze-Eastern agree to an acquisition of Breeze-Eastern for $19.61/share in cash)<br/><br/><b>Select small cap biotech related names showing strength</b>: MCUR +32.5%, CAPN +20.8%, SPHS +8.9%, PHMD +3.6%, APPY +3.2%, ORMP +3%, SNTA +2.8%<br/><br/><b>Select metals/mining stocks trading higher:</b> MTL +7.3%, AU +3.6%, MT +2.9%, BHP +1.7%, BBL +1.3%, RIO +1.2%, AA +1.1%, VALE +1%, GDX +0.6%<br/><br/><b>Other news:</b> KBIO +663.8% (Former Retrophin CEO and current Turing Pharma CEO Martin Shkreli discloses ownership of ~1.625 mln shares; ~1.2 mln shares purchased from 11/16 to 11/17 at prices ranging from $0.30-2.45 per share ), STEM +53.8% (announces that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury showed motor improvements in both strength and function), NLST +51.5% (entered into a five year Joint Development and License Agreement w/ Samsung Electronics (SSNLF) to produce a new class of NVDIMM-P memory solutions), UNXL +34% (receives initial mass production order from Japanese PC manufacturer), VTAE +23.3% (announced positive top-line results from a Phase 1 multiple ascending dose trial of VTP-43742; shown to be safe and generally well tolerated in healthy human volunteers), SFXE +23.2% (light volume, pre-mkt rebound following yday's news), HART +21.9% (small cap biotech peer; CFO disclosed small purchase last night -- 10K shares), VTL +15.7% (received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial), VBLT +13% (announces significant improvement of 12 Month overall survival with VB-111), TUMI +6.5% (to replace IPCM in the S&P SmallCap 600), PLPM +6.4% (signs multi-currency processing agreement with BBVA Bancomer and launches its integrated payments hospitality solution for BBVA Bancomer merchants ), ATHX +4% (reports that multipotent adult progenitor cells, used in its MultiStem cell therapy, are effective in improving the health of animals after acute rodent spinal cord injury), ZIOP +3.8% (will present initial results from its Phase 1 dose-escalation study of Ad-RTS-hIL-12), RTN +2.9% (affirms $0.67/share quarterly dividend, adds $2 bln to repurchase program ), FIT +2.4% (favorable commentary on Wednesday's Mad Money), CETV +2.3% (TCS Capital Management discloses 10.9% active stake in 13D filing; TCS sends letter to Board urging pursuit of strategic alternatives), CLLS +1.7% (Servier Exercises signs exclusive worldwide licensing option with Cellectis for UCART19), VOD +1.3% (announces its intention to raise around £500 million of new debt issuance of non-dilutive equity-linked bonds due 2020), DAL +1% (announces its intention to acquire up to an additional 32% of the outstanding capital stock of Grupo Aeromexico S.A.B. through a cash tender offer for MXP$43.59/share)<br/><br/><b>Analyst comments:</b> TTPH +8.6% (upgraded to Buy from Neutral at Sun Trust Rbsn Humphrey), WEN +2.8% (added to Conviction Buy List at Goldman), NGG +1.4% (upgraded to Outperform at RBC Capital Mkts), SUN +1.3% (upgraded to Outperform from Neutral at Credit Suisse)<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b> LQDT -16.2%, SSI -11.5%, EDAP -10.1%, JKS -8.2%, SMTC -7.5%, UNH -6.1%, BBY -4.2%, BKE -1.5%, SMRT -1.2%, IGLD -1%<br/><br/><b>M&A news: </b>SYT -2.3% (cont volatility surrounding M&A spec)<br/><br/><b>Other news: </b>NBG -17.1% (cont weakness), AMAG -10.2% (received Complete Response Letter from the FDA for Makena (hydroxyprogesterone caproate injection) for the reduction of the risk of preterm birth), VLP -9.1% (announces an underwritten public offering of 4.25 mln units ), SUNE -4.9% (Blackstone denying speculation related to debt investment), AET -4.1% (in symp with UNH), RDY -2.8% ( issues statement related to recent media reports; co states it has always adhered to international accounting practices), HUM -2.4% (in symp with UNH), AGN -1.8% (Allergan, Pfizer (PFE) near a deal under which Pfizer would acquire Allergan for as much as $380/share, according to BloombergWSJ reporting Treasury Department might issue anti inversion tax rules this week), DVA -1.6% (co's subsidiary received Civil Investigative Demand from the U.S. Department of Justice), RMAX -1.6% (prices secondary offering of 4,500,000 shares of common stock by its controlling stockholder, RIHI, at $36.00 per share), EQIX -1.6% (prices offering of 2,604,167 shares of common stock at $288.00 per share), BFAM -1.5% (announces pricing of its 3.65 mln share secondary offering by selling stockholders at $63.80/share)<br/><br/><b>Analyst comments:</b> TWI -7.7% (downgraded to Sell from Neutral at Goldman )<br/><br/>Allikas: Briefing.com